By demonstrating that an endogenous peptide can modulate calcineurin signaling and peripheral/CNS cytokine profiles in a mitochondrial toxin PD model, this study identifies a biologically plausible, targetable mechanism (CaN-driven inflammation) with translational potential for early-stage PD…

It identifies actionable, PD-relevant mechanisms (NF-κB/MAPK anti-inflammatory effects, Nrf2 antioxidant activation, BDNF-related synaptic support, and mitigation of α-synuclein aggregation) that support luteolin as a repurposing/formulation target for neuroprotective strategies in Parkinson's…

Identifies modifiable lipid-related pathways (diet, BBB integrity, inflammation, mitochondrial dysfunction) that are relevant to PD therapeutic discovery and biomarker development, offering translational hypotheses despite being largely conceptual and needing experimental validation.

By implicating systemic mitochondrial impairment measurable in blood, the work supports mitochondria-targeted biomarker and therapeutic strategies that could be relevant to Parkinson’s disease research, though results are preliminary and specific to PSP.

Provides a noninvasive imaging biomarker linking iron/inflammation topography to clinical phenotype in 4‑repeat tauopathies, aiding patient stratification, diagnostic accuracy, and mechanistic or therapeutic targeting of neuroinflammation/iron-related pathology.

Offers useful perspectives on immune-reprogramming strategies and neuroinflammation that could inform Parkinson's immunotherapies, while flagging crucial safety risks (neurotoxicity/parkinsonism) relevant for translating cell-based approaches to PD.

Provides a clear, actionable mechanism—lipid remodeling via C14:0—that reverses α-synuclein pathogenic phenotypes in patient neurons and offers a plausible translational path for lipid-based or metabolic therapies in PD.

By defining a DAPK1→parkin→MITOL pathway that links mitochondrial dysfunction to reduced parkin-mediated neuroprotection, the work highlights DAPK1 inhibition or preservation of parkin as actionable therapeutic strategies for Parkinson's disease.

By linking PINK1 to gut-brain interactions, glutathione-dependent redox failure, and a defined neuronal transcriptional pathway, this study reveals actionable targets (antioxidant/glutathione pathways, gut microbial control, and DGK-related signaling) for therapeutic exploration in PD despite the…

Links two major PD-relevant pathways (LRRK2 and GCase/lysosomal lipid handling) to a drug-modifiable EV-associated biomarker (BMP-positive EVs), offering mechanistic insight and translational leads for diagnostics and therapies targeting lysosomal dysfunction in Parkinson's.

By enabling sensitive intracellular and red-shifted detection of α-synuclein assemblies with low cytotoxicity, these probes are valuable tools for studying aggregation kinetics, cellular pathology, and for screening or validating therapeutics and biomarkers relevant to Parkinson's disease.

It synthesizes actionable genome‑editing approaches and preclinical models that directly inform development of targeted, potentially disease‑modifying therapies for PD while outlining key barriers to clinical translation.

NAC is a well-tolerated, mechanistically plausible glutathione precursor that shows preliminary dopaminergic biomarker effects in PD, supporting prioritized, well-powered randomized trials with standardized oxidative stress and dopaminergic biomarker endpoints for therapeutic repurposing.

Indicates a translatable, nonpharmacological intervention that may enhance goal-directed motor behavior via mood/apathy modulation and uses objective wearable measures for functional readouts, though it lacks molecular disease‑modifying mechanism data.

By linking PUFA/oxylipin dysregulation, inflammation (COX pathways), and alpha-synuclein biology, the paper identifies a mechanistically plausible, targetable lipid-inflammatory axis with biomarker potential and actionable translational leads (e.g., PUFA modulation, COX-related interventions) for…

Identifies accessible peripheral exocrine tissues as potential prodromal biomarkers and windows into autonomic alpha-synuclein pathology that could aid early diagnosis and patient stratification, offering translational value despite limited direct novel molecular targets for drug development.

Although neither tracer is immediately translatable, the negative and comparative data clarify tracer selectivity, off-target liabilities, and species metabolic differences that are directly actionable for designing better α‑synuclein PET ligands to support Parkinson's therapeutic development and…

While observational and lacking mechanistic detail, the result highlights IGF‑1 as a promising prognostic biomarker and a candidate pathway for developing neuroprotective or symptom‑modifying interventions targeting non‑motor features in PD.

Aggregates mechanistic evidence that plant extracts can target inflammation, oxidative stress and α‑synuclein—areas of high therapeutic interest for disease modification—while flagging important translational gaps (heterogeneity, standardization, dosing, bioavailability) that limit immediate…

Sleep is an important non-motor symptom in PD; this trial evaluates a low-cost, non-pharmacologic rehabilitative approach with objective sleep outcomes and safety data that could inform larger, pragmatic trials and offer a new symptomatic management option.

Provides clinically actionable information for developing and optimizing device‑aided symptomatic treatments and access pathways, but offers limited mechanistic or disease‑modifying insight for therapeutic discovery.

Though focused on cardiac disease, the work links AMPK-driven bioenergetic and mitochondrial dysfunction to pathology and demonstrates metformin can reverse those defects, offering indirect mechanistic and repurposing insight for Parkinson's strategies that target AMPK, mitochondrial/metabolic…

Clinically useful for therapeutic decision-making and risk mitigation in PD (monitoring, prescribing choices, and need for alternative strategies), but provides limited mechanistic or biomarker insights to directly drive novel drug discovery.

While this study has low direct value for therapeutic discovery, it identifies gaps in patient-facing exercise guidance that are important for improving dissemination, adherence to rehabilitation protocols, and ultimately the implementation of evidence-based nonpharmacologic interventions.

Offers a translationally relevant, infection-driven platform to study inflammation-mediated PD mechanisms and to test anti-inflammatory/antiviral or neuroprotective interventions, though its value hinges on how well it reproduces key PD features (e.g., alpha-synuclein aggregation, progressive…